A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients

Clinical Trial

. 2003 Oct 15;9(13):4756-60.

Affiliations

PMID: 14581346

Clinical Trial

Tetsuro Higuchi et al. Clin Cancer Res. 2003.

Abstract

Purpose: The aim of this study was to examine the effect of a specific cyclooxygenase-2 inhibitor, rofecoxib, on rectal polyps in familial adenomatous polyposis patients.

Experimental design: This was a randomized, double-blind, placebo-controlled study of the efficacy and safety of rofecoxib in the rectum. Initially, 21 patients were assigned randomly in a 1:1 ratio to receive either 25 mg rofecoxib once a day or a placebo p.o. for 9 months. Patients underwent endoscopy at the beginning of the study and then every 3 months thereafter. We reviewed the videotapes to measure the number and size of polyps in the same area throughout the study period in each individual patient.

Results: The polyp number, measured as the percentage of change from the baseline values, was significantly decreased in the rofecoxib group at 3, 6, and 9 months. At 9 months, the polyp number in the rofecoxib group decreased by 6.8% from the baseline values, whereas that in the placebo group increased by 3.1%. The 9.9% difference between the rofecoxib and placebo groups was statistically significant (P = 0.004). At 9 months, the rofecoxib group showed a significant reduction from the baseline in polyp size as compared with the placebo group (-16.2% versus 1.5%; P < 0.001). There was no statistically significant increase in the incidence of any adverse events in treatment with rofecoxib compared with placebo (P = 0.922).

Conclusions: In this study, once-daily treatment with 25 mg rofecoxib, a cyclooxygenase 2-specific inhibitor, significantly decreased the number and size of rectal polyps in familial adenomatous polyposis patients.

PubMed Disclaimer

Cited by

Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.
Wong CC, Cheng KW, Rigas B. Wong CC, et al. J Pharmacol Exp Ther. 2012 Jun;341(3):572-8. doi: 10.1124/jpet.112.191957. Epub 2012 Mar 23. J Pharmacol Exp Ther. 2012. PMID: 22448039 Free PMC article.
Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis.
Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA, Neuhausen SL, Stram DO, Ursin G, Anton-Culver H. Zell JA, et al. Cancer. 2009 Dec 15;115(24):5662-71. doi: 10.1002/cncr.24705. Cancer. 2009. PMID: 19827153 Free PMC article.
Early-onset colorectal cancer: initial clues and current views.
Hofseth LJ, Hebert JR, Chanda A, Chen H, Love BL, Pena MM, Murphy EA, Sajish M, Sheth A, Buckhaults PJ, Berger FG. Hofseth LJ, et al. Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):352-364. doi: 10.1038/s41575-019-0253-4. Epub 2020 Feb 21. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32086499 Free PMC article. Review.
Chemoprevention in patients with genetic risk of colorectal cancers.
Laukaitis CM, Erdman SH, Gerner EW. Laukaitis CM, et al. Colorectal Cancer. 2012;1(3):225-240. doi: 10.2217/crc.12.22. Colorectal Cancer. 2012. PMID: 25221625 Free PMC article.
Nonsteroidal Anti-inflammatory Drugs for Chemoprevention in Patients With Familial Adenomatous Polyposis: A Systematic Review and Meta-Analysis.
Farooq U, El Alayli A, Duvvuri A, Mansour R, Pasam RT, Malireddy S, Mustafa RA, Bansal A. Farooq U, et al. Gastro Hep Adv. 2023 Jun 10;2(7):1005-1013. doi: 10.1016/j.gastha.2023.05.009. eCollection 2023. Gastro Hep Adv. 2023. PMID: 39130765 Free PMC article. Review.

A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients - PubMed (original) (raw)